SG11201808626WA - Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors - Google Patents

Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Info

Publication number
SG11201808626WA
SG11201808626WA SG11201808626WA SG11201808626WA SG11201808626WA SG 11201808626W A SG11201808626W A SG 11201808626WA SG 11201808626W A SG11201808626W A SG 11201808626WA SG 11201808626W A SG11201808626W A SG 11201808626WA SG 11201808626W A SG11201808626W A SG 11201808626WA
Authority
SG
Singapore
Prior art keywords
inhibitors
administering
combination
tumor burden
reducing tumor
Prior art date
Application number
SG11201808626WA
Other languages
English (en)
Inventor
Israel Charo
Heiyoun Jung
Thomas Schall
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11201808626WA publication Critical patent/SG11201808626WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201808626WA 2016-04-07 2017-04-06 Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors SG11201808626WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319689P 2016-04-07 2016-04-07
PCT/US2017/026290 WO2017176965A1 (en) 2016-04-07 2017-04-06 Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201808626WA true SG11201808626WA (en) 2018-10-30

Family

ID=59999231

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808626WA SG11201808626WA (en) 2016-04-07 2017-04-06 Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Country Status (20)

Country Link
US (2) US10568870B2 (enrdf_load_stackoverflow)
EP (1) EP3439653B1 (enrdf_load_stackoverflow)
JP (2) JP7539231B2 (enrdf_load_stackoverflow)
KR (1) KR102370704B1 (enrdf_load_stackoverflow)
CN (1) CN109310677A (enrdf_load_stackoverflow)
AR (1) AR108202A1 (enrdf_load_stackoverflow)
AU (1) AU2017246460B2 (enrdf_load_stackoverflow)
BR (1) BR112018070361A2 (enrdf_load_stackoverflow)
CA (1) CA3019391A1 (enrdf_load_stackoverflow)
DK (1) DK3439653T3 (enrdf_load_stackoverflow)
ES (1) ES2864148T3 (enrdf_load_stackoverflow)
IL (1) IL261998B2 (enrdf_load_stackoverflow)
MX (1) MX384929B (enrdf_load_stackoverflow)
PL (1) PL3439653T3 (enrdf_load_stackoverflow)
PT (1) PT3439653T (enrdf_load_stackoverflow)
RU (1) RU2745195C2 (enrdf_load_stackoverflow)
SG (1) SG11201808626WA (enrdf_load_stackoverflow)
TW (1) TWI808938B (enrdf_load_stackoverflow)
WO (1) WO2017176965A1 (enrdf_load_stackoverflow)
ZA (1) ZA201806633B (enrdf_load_stackoverflow)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015012842B1 (pt) 2012-12-07 2022-06-07 Chemocentryx, Inc Compostos derivados de diazol lactama, composição farmacêutica e uso dos mesmos
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
DK3431105T3 (da) * 2017-03-29 2020-03-09 Shionogi & Co Medicinsk sammensætning til behandling af cancer
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
WO2019023575A1 (en) 2017-07-28 2019-01-31 Chemocentryx, Inc. IMMUNOMODULATORY COMPOUNDS
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
KR20200103020A (ko) 2017-12-22 2020-09-01 코다제닉스 인코포레이티드 코돈쌍 탈최적화 영역을 가진 재조합 바이러스 및 암 치료를 위한 이의 용도
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
CA3091508A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
AU2019285640A1 (en) * 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
AU2019285641A1 (en) 2018-06-15 2021-04-08 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
EP3843711A4 (en) * 2018-08-29 2022-08-03 ChemoCentryx, Inc. METHODS OF CANCER TREATMENT WITH SMALL MOLECULE PD-L1 INHIBITORS
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
JP2022501361A (ja) 2018-09-19 2022-01-06 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｃｄ８０融合タンパク質および関連構築物の方法および使用
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
DK3880186T3 (da) 2018-11-14 2024-06-03 Regeneron Pharma Intralæsional administration af pd-1-hæmmere til behandling af hudcancer
AU2020228296B2 (en) 2019-02-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Administration of PD-1 inhibitors for treating skin cancer
WO2020180727A1 (en) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
MX2022000318A (es) 2019-07-10 2022-02-10 Chemocentryx Inc Indanos como inhibidores de pd-l1.
US20230030597A1 (en) * 2019-09-11 2023-02-02 Boehringer Ingelheim Io Canada Inc. Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
GB201918692D0 (en) 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer
US20230331858A1 (en) * 2019-12-24 2023-10-19 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
EP4157464A1 (en) 2020-05-26 2023-04-05 Regeneron Pharmaceuticals, Inc. Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
WO2022046833A1 (en) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a pd-1 inhibitor
CN116194142A (zh) 2020-09-03 2023-05-30 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症疼痛的方法
WO2022081572A1 (en) * 2020-10-13 2022-04-21 Board Of Regents, The University Of Texas System Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment
WO2022204672A1 (en) 2021-03-23 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
IL310201A (en) 2021-07-19 2024-03-01 Regeneron Pharma Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
KR20240149434A (ko) 2022-02-17 2024-10-14 리제너론 파마슈티칼스 인코포레이티드 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합
WO2023230220A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2025080538A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539091A1 (de) 1995-10-20 1997-04-24 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
WO2004098528A2 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
CA2609051A1 (en) 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
BRPI0612112A8 (pt) 2005-06-22 2017-12-26 Chemocentryx Inc composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.
FR2887450B1 (fr) 2005-06-23 2007-08-24 Rhodia Chimie Sa Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
JPWO2007026834A1 (ja) 2005-09-01 2009-03-12 クミアイ化学工業株式会社 ピラゾール誘導体及び農園芸用除草剤
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
US20090252779A1 (en) 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
WO2008072724A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. ピラゾール誘導体
US7786157B2 (en) 2007-03-16 2010-08-31 Chemocentryx, Inc. OXO-imidazolidines as modulators of chemokine receptors
WO2008147815A1 (en) 2007-05-22 2008-12-04 Chemocentryx, Inc. 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
WO2009002933A1 (en) 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders
CA2705502C (en) 2007-11-13 2016-01-26 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
WO2009140519A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
KR101743140B1 (ko) 2008-09-11 2017-06-02 케모센트릭스, 인크. ４-아미노-３-(이미다졸릴)-피라졸로〔３,４-ｄ〕피리미딘
EP3530672B1 (en) 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
EP3309175A1 (en) 2012-05-15 2018-04-18 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AR091220A1 (es) 2012-05-31 2015-01-21 Genentech Inc Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
RU2646762C2 (ru) * 2012-08-27 2018-03-07 Кемосентрикс, Инк. Антагонисты хемокиновых рецепторов
BR112015012842B1 (pt) 2012-12-07 2022-06-07 Chemocentryx, Inc Compostos derivados de diazol lactama, composição farmacêutica e uso dos mesmos
DK2935227T3 (en) 2012-12-21 2017-12-04 Chemocentryx Inc DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
KR20230118704A (ko) * 2013-07-16 2023-08-11 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을치료하는 방법
US9827309B2 (en) 2013-08-20 2017-11-28 Merck Sharp & Dohme Corp. Treating cancer with a combination of a PD-1 antagonist and dinaciclib
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
LT3041827T (lt) 2013-09-06 2018-07-25 Aurigene Discovery Technologies Limited 1,2,4-oksadiazolo dariniai, kaip imunomoduliatoriai
ES2683356T3 (es) 2013-09-06 2018-09-26 Aurigene Discovery Technologies Limited Compuestos peptidomiméticos cíclicos como inmunomoduladores
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3904388A1 (en) * 2014-05-27 2021-11-03 Academia Sinica Fucosidase from bacteroides and methods using the same
SG10202007111TA (en) * 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
AU2016230795A1 (en) 2015-03-10 2017-09-07 Aurigene Discovery Technologies Limited Therapeutic cyclic compounds as immunomodulators
MX2017011612A (es) 2015-03-10 2018-03-23 Aurigene Discovery Tech Ltd Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores.
RS62960B1 (sr) 2015-03-10 2022-03-31 Aurigene Discovery Tech Ltd Jedinjenja 1,2,4-oksadiazola i tiadiazola kao imunomodulatori
EA201791634A1 (ru) 2015-03-10 2018-03-30 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
EP3267999A4 (en) 2015-03-10 2018-07-25 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10110466B2 (en) * 2015-11-23 2018-10-23 Tyco Electronics Subsea Communications Llc Optical communication system with distributed wet plant manager
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷

Also Published As

Publication number Publication date
IL261998B2 (en) 2023-03-01
ZA201806633B (en) 2021-04-28
TWI808938B (zh) 2023-07-21
ES2864148T3 (es) 2021-10-13
US11744822B2 (en) 2023-09-05
IL261998A (en) 2018-10-31
BR112018070361A2 (pt) 2019-01-29
KR102370704B1 (ko) 2022-03-03
JP7539231B2 (ja) 2024-08-23
IL261998B (en) 2022-11-01
RU2018138828A (ru) 2020-05-15
NZ746960A (en) 2025-05-30
AR108202A1 (es) 2018-07-25
KR20190020291A (ko) 2019-02-28
EP3439653A4 (en) 2019-12-04
RU2018138828A3 (enrdf_load_stackoverflow) 2020-08-12
MX2018012132A (es) 2019-03-28
CA3019391A1 (en) 2017-10-12
DK3439653T3 (da) 2021-03-29
TW201801724A (zh) 2018-01-16
EP3439653B1 (en) 2021-01-20
CN109310677A (zh) 2019-02-05
US20170290808A1 (en) 2017-10-12
RU2745195C2 (ru) 2021-03-22
MX384929B (es) 2025-03-14
PL3439653T3 (pl) 2021-07-05
AU2017246460B2 (en) 2021-04-22
WO2017176965A1 (en) 2017-10-12
JP7611189B2 (ja) 2025-01-09
JP2019510832A (ja) 2019-04-18
US20200289472A1 (en) 2020-09-17
US10568870B2 (en) 2020-02-25
AU2017246460A1 (en) 2018-10-25
PT3439653T (pt) 2021-03-25
EP3439653A1 (en) 2019-02-13
JP2022130424A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
ZA201806633B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
IL276314A (en) Preparations for the treatment of cancer using PD-1 axis binding antagonists and MEK inhibitors
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL249133B (en) A method for treating cancer with antagonists against pd-1 and pd-l1 in combination with radiation therapy
IL252251A0 (en) Combined treatment including ox40 binding agonists and axispd-1 binding antagonists
IL263110A (en) Combined treatment of notch and pd-1 or pd-l1 inhibitors
IL256166B (en) Compounds for use in the treatment of neuromuscular disorders
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
SG11201607392SA (en) Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
PL3509512T3 (pl) Kaniula do stosowania do wstrzyknięć śródkostnych
EP3223793A4 (en) Compositions and methods for delivering a bio-active agent or bio-active agents
IL246855A0 (en) Materials for use in the treatment of retinitis
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
EP3194030A4 (en) Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv
HK40004572A (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer